Company Encyclopedia
View More
name
SHYNDEC
600420.SH
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydrochloride for injection, sodium cefuroxime for injection, ceftriaxone sodium crude salt, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, 7-ACA, amlodipine besylate tablets, cefoperazone dispersible tablets, and amoxicillin capsules. Shanghai Shyndec Pharmaceutical Co., Ltd.
3.157 T
600420.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking98/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE6.96%C
    • Profit Margin10.04%B
    • Gross Margin28.84%C
  • Growth ScoreD
    • Revenue YoY-19.45%E
    • Net Profit YoY-14.06%D
    • Total Assets YoY-3.66%D
    • Net Assets YoY3.33%C
  • Cash ScoreC
    • Cash Flow Margin995.91%B
    • OCF YoY-19.45%E
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreA
    • Gearing Ratio18.79%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic

    Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic

    marketscreener·
    SH
    600420
    +0.19%
    marketscreener·
    SH
    600420
    +0.19%

    Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution

    Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution

    marketscreener·
    SH
    600420
    +0.19%
    marketscreener·
    SH
    600420
    +0.19%

    SHYNDEC's holding subsidiary signs the "Drug Marketing Authorization Transfer Agreement"

    SHYNDEC's subsidiary Guoyao Zhijun Ping Shan signed a "Drug Marketing Authorization Transfer Agreement" with Anhui Meilai, transferring the marketing authorization for Lactulose Oral Solution (15ml:10g) for a transfer fee of 5.86 million yuan. This move aims to enrich the company's product pipeline, enhance market competitiveness, and aligns with the company's medium to long-term development strategy. This matter has no significant impact on the company's current operating performance

    Zhitong·
    SH
    600420
    +0.19%
    Zhitong·
    SH
    600420
    +0.19%

    SHYNDEC: Famotidine injection has passed the consistency evaluation of quality and efficacy for generic drugs

    SHYNDEC announced that its wholly-owned subsidiary China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for Famotidine injection to pass the consistency evaluation of quality and efficacy for generic drugs. Famotidine is a histamine H2 receptor antagonist used to treat peptic ulcers and related bleeding

    Zhitong·
    SH
    600420
    +0.19%
    Zhitong·
    SH
    600420
    +0.19%

    Shyndec Pharmaceutical's Unit Gets Nod to Market Sitagliptin Phosphate

    Shyndec Pharmaceutical's Unit Gets Nod to Market Sitagliptin Phosphate

    marketscreener·
    SH
    600420
    +0.19%
    marketscreener·
    SH
    600420
    +0.19%
    © 2025 Longbridge｜Disclaimer